Drug distributor McKesson and private equity firm Clayton Dubilier & Rice announced Tuesday they will take Option Care Health private in a transaction valued at $5.8 billion enterprise value. The deal splits ownership of the largest independent provider of home and alternate-site infusion services in the United States between a strategic buyer with existing specialty pharmacy infrastructure and a PE firm that has owned pieces of the healthcare services value chain for two decades.
Option Care operates 109 infusion pharmacy locations across 38 states, treating roughly 190,000 patients annually with complex therapies including immunoglobulin, anti-infectives, parenteral nutrition, and specialty injectables. The company reported $4.7 billion in revenue for the twelve months ending June 2024 and serves as the contracted infusion partner for half the top 20 payers by covered lives. McKesson already distributes pharmaceuticals to Option Care facilities under a national supply agreement signed in 2021. CD&R has held positions in Envision Healthcare, Air Methods, and US Acute Care Solutions over the past decade, each a bet on the migration of acute care to lower-cost settings.
The timing matters. CMS finalized 2025 reimbursement rates for home infusion therapy on September 28, raising the payment floor for certain immunoglobulin and antibiotic protocols by 4.2% after three years of cuts that compressed margins across the sector. That clarity removes one variable that kept Option Care's multiple compressed at 12.1x trailing EBITDA when its publicly traded peers in specialty pharmacy trade north of 15x. McKesson gains immediate optionality to route higher-margin specialty drugs through a captive infusion network instead of hospital outpatient departments, which reimburse at rates 40-60% higher for identical therapies. The company's existing specialty health segment generated $13.2 billion in revenue last fiscal year, and vertical integration into the infusion endpoint opens $800 million to $1.1 billion in annual purchasing synergies according to sell-side models published in the last six months.
CD&R's participation signals confidence that the structural shift from hospital-based to home-based infusion will outlast any single reimbursement cycle. Private payers now steer 68% of complex biologic starts to home infusion when the patient is clinically appropriate, up from 51% in 2019, driven by per-episode cost differences that exceed $3,000 for a standard IVIG course. Option Care's nursing workforce of 3,400 clinicians becomes the operational moat. Training a registered nurse to manage central line access and administer high-risk biologics at home takes 9-12 months, and turnover in home infusion nursing runs 23% annually, well above the 16% average for hospital-based specialty nursing. Retention infrastructure is harder to replicate than pharmacy licenses.
Allocators should track how quickly McKesson redirects specialty pharmaceutical volume through the Option Care network post-close, expected in Q2 2025 pending regulatory clearance. The company will report December quarter results in early February, and any commentary on specialty drug placement strategy will clarify whether this is a defensive margin move or an offensive growth play. Watch for competitive responses from Cardinal Health and AmerisourceBergen, both of which lack owned infusion assets but have distribution agreements with regional players. If either announces an acquisition or joint venture in the home infusion segment within 90-120 days, the signal is that all three major distributors see margin pressure in traditional wholesale and need downstream exposure.
The deal prices Option Care at 1.23x trailing revenue, a 19% premium to its 90-day volume-weighted average share price, but in line with what CD&R paid per revenue dollar for Air Methods in 2015 and what McKesson itself paid for RxCrossroads in 2022. The infrastructure is purchased. The reimbursement floor is set. The nursing staff stays in place. What remains is execution on the redirect.
The takeaway
McKesson buys the infusion endpoint to route high-margin biologics, CD&R bets home care infrastructure outlasts reimbursement cycles.
Editorial & Disclosure Notice: This article was written with artificial intelligence from public sources and is published without individual human review. Artificial intelligence and other digital tools are also used for research, analysis, editing, formatting, and production. Errors, omissions, outdated information, or inaccuracies may occur. References to companies, brands, products, services, organizations, or individuals are for informational and editorial purposes and do not imply endorsement, sponsorship, affiliation, partnership, or approval unless expressly stated. All trademarks and other intellectual property remain the property of their respective owners. Opinions, analysis, estimates, and commentary are informational only and should not be construed as financial, investment, legal, tax, medical, procurement, or other professional advice. Information may be corrected, clarified, or updated after publication. Corrections or removal requests: jenny@pops4.com.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.